Long a major presence in the orthopedic market, recent years have seen Stryker push into other areas. Perhaps most notably, it paid $1.5 billion to take on Boston Scientific’s neurovascular business in late 2010. Stryker also sold off its OP-1 putty business for pennies on the dollar, looking to put a disastrous off-label promotion scandal in its rear-view mirror (a federal case against the biotech business and several former executives finally resolved this year). The company stunned the orthopedics world early in 2012 with the abrupt departure of well-regarded CEO Steve MacMillan.
Home » Stryker Corp